Cancer Vaccine Using Novel ESR1 Derived Peptides For Neoantigen Therapy

FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICE

Contact

Haskell Adler PhD MBA CLP
Senior Licensing Manager
Haskell.Adler@Moffitt.org
(813) 745-6596

20MB062N - VIDEO